

CERTIFICATE

Survey of 30 January 2026

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Thyroid Hormones (294):

Validity 6 months:

free T3 (triiodothyronine) (R: B1a)

free T4 (thyroxine) (R: B1a)

Validity 12 months:

T3 total

T4 total (Thyroxine)

(R) analysis is subject to the RiliBÄK

Customer:

10043733

CG Cytogenomics Medical Laboratory

CG Cytogenomics

313 Hrakleiou Av.

14122 Neo Irakleio



Düsseldorf, 04 February 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 30 January 2026

You have participated in the External Quality Assessment with the following analysis

Thyroid Hormones (294):

T3 total

T4 total (Thyroxine)

TSH (R: B1a)

free T3 (triiodothyronine) (R: B1a)

free T4 (thyroxine) (R: B1a)

(R) analysis is subject to the RiliBÄK

Customer:

10043733

CG Cytogenomics Medical Laboratory

CG Cytogenomics

313 Hrakleiou Av.

14122 Neo Irakleio



Düsseldorf, 04 February 2026



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Dr. med. Jürgen Durner
(Adviser)

Listing and evaluation of the results

10043733: CG Cytogenomics Medical Laboratory
CG Cytogenomics

Survey of 30 January 2026

Adviser:

Prof. Dr. rer. nat. Dr. med. Jürgen Durner
Labor Becker MVZ GbR
Führichstr. 70
81671 München

Tel.: +49 89 450 917 349
Fax: +49 89 450 917 6349
Mail: j.durner@labor-becker.de

294

Thyroid Hormones

Analyte	Sample 294A- 260113	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
T3 total	-01	nmol/l	0.691	0.488	ET	0.025	0.941	41.6%	0,634	+	
	-02		6.07	4.51	ET	0.610	8.41	34.5%	0,529	+	
T4 total (Thyroxine)	-01	nmol/l	41.2	39.7	SV	30.2	49.2	3.7%	0,185	+	
	-02		179	174	SV	132	216	2.8%	0,272	+	
TSH	-01	mU/l	10730	10.8	SV	8.21	13.4	99251.9%	17925	-	
	-02		390	0.395	SV	0.300	0.490	98634.2%	11806	-	
free T3 (triiodothyronine)	-01	pmol/l	2.67	2.72	SV	2.18	3.26	-1.7%	-0,181	+	
	-02		19.2	19.1	SV	15.3	22.9	0.6%	0,104	+	
free T4 (thyroxine)	-01	pmol/l	6.82	7.71	SV	6.17	9.25	-11.5%	-1,19	+	
	-02		35.9	37.3	SV	29.8	44.8	-3.7%	-0,729	+	

Analyte	Sample 294A- 260113	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device
T3 total	-01	ng/ml	0.450	1.54	228	BG	BG17
	-02		3.95	1.54			
T4 total (Thyroxine)	-01	µg/dl	3.20	12.9	228	BG	BG17
	-02		13.9	12.9			
TSH	-01	mIU/ml	10.7	1000	228	BG	BG17
	-02		0.390	1000			
free T3 (triiodothyronine)	-01	pg/ml	1.74	1.54	228	BG	BG17
	-02		12.5	1.54			
free T4 (thyroxine)	-01	ng/dl	0.530	12.9	228	BG	BG17
	-02		2.79	12.9			

Additional information on the evaluation is available for download in the RV-Online system in the column "Report".

Individual summary of results

10043733: CG Cytogenomics Medical Laboratory
CG Cytogenomics

Survey of 30 January 2026


294

Thyroid Hormones

T3 total (nmol/l, N = 17)

Collective	Sample 294A- 260113	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
Roche	-01	0.950	0.722 - 1.18	0.950	11.7	9	88.9	88.9	
	-02	6.18	4.70 - 7.66	6.18	5.34	9	100		
other providers	-01	0.488	0.025 - 0.941	0.488	65.6	8	87.5	75.0	
	-02	4.51	0.610 - 8.41	4.51	65.4	8	75.0		


Rate of success: 82,4%



T4 total (Thyroxine) (nmol/l, N = 14)

Collective	Sample 294A- 260113	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all providers	-01	39.7	30.2 - 49.2	39.7	20.5	14	78.6	78.6	
	-02	174	132 - 216	174	10.6	14	78.6		

Rate of success: 78,6%




TSH (mU/l, N = 353)

Collective	Sample 294A- 260113	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Abbott	-01	9.70	7.37 - 12.0	9.70	4.27	37	100	97.3
	-02	0.351	0.267 - 0.435	0.351	6.84	37	97.3	
BIOMERIEUX	-01	13.0	9.88 - 16.1	13.0	8.08	16	100	100
	-02	0.392	0.298 - 0.486	0.392	9.18	16	100	
Beckman	-01	9.80	7.45 - 12.2	9.80	5.37	25	92.0	84.0
	-02	0.385	0.293 - 0.477	0.385	5.71	25	88.0	
Siemens (Bayer Health, DPC)	-01	10.8	8.21 - 13.4	10.8	5.54	30	93.3	93.3
	-02	0.395	0.300 - 0.490	0.395	8.35	30	93.3	
Siemens (DB) - LOCI	-01	9.81	7.46 - 12.2	9.81	3.91	17	100	100
	-02	0.380	0.289 - 0.471	0.380	4.74	17	100	
RadioImmunoAssay (1)	-01	9.31	7.08 - 11.5	9.31	4.99	2		
	-02	0.400	0.304 - 0.496	0.400	8.00	2		
Diasorin (1)	-01	14.4	10.9 - 17.9	14.4	2.42	6		
	-02	0.378	0.287 - 0.469	0.378	6.61	6		
Roche	-01	10.8	8.21 - 13.4	10.8	5.19	207	99.0	98.6
	-02	0.417	0.317 - 0.517	0.417	4.08	207	98.6	
Tosoh (1)	-01	12.3	9.35 - 15.3	12.3	11.4	5		
	-02	0.392	0.298 - 0.486	0.392	8.67	5		
other providers	-01	11.9	6.38 - 17.4	11.9	35.0	8	87.5	87.5
	-02	0.498	0.309 - 0.687	0.498	28.7	8	87.5	

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.


Rate of success: 96,6%


free T3 (triiodothyronine) (pmol/l, N = 273)

Collective	Sample 294A- 260113	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Abott	-01	2.40	1.92 - 2.88	2.40	5.08	29	100	100
	-02	18.3	14.6 - 22.0	18.3	4.87	29	100	
Biomerieux	-01	1.49	1.19 - 1.79	1.49	17.9	11	72.7	72.7
	-02	15.8	12.6 - 19.0	15.8	7.28	11	100	
Beckman	-01	2.28	1.82 - 2.74	2.28	15.7	19	78.9	78.9
	-02	15.0	12.0 - 18.0	15.0	6.80	19	100	
Siemens (Bayer Health)	-01	2.72	2.18 - 3.26	2.72	10.2	15	93.3	93.3
	-02	19.1	15.3 - 22.9	19.1	5.03	15	100	
Siemens (Dade Behring, DPC)	-01	1.44	1.15 - 1.73	1.44	15.8	12	83.3	83.3
	-02	17.0	13.6 - 20.4	17.0	2.02	12	100	
Siemens (DPC Biemann) (1)	-01	2.00	1.60 - 2.40	2.00	10.8	7		
	-02	12.7	10.2 - 15.2	12.7	4.79	7		
Diasorin (1)	-01	2.15	1.72 - 2.58	2.15	13.3	7		
	-02	17.9	14.3 - 21.5	17.9	10.2	7		
RadioImmunoAssay (1)	-01	2.40	1.92 - 2.88	2.40	0.000	1		
	-02	14.6	11.7 - 17.5	14.6	0.000	1		
Roche	-01	2.54	2.03 - 3.05	2.54	9.21	167	96.4	95.2
	-02	22.0	17.6 - 26.4	22.0	4.07	167	98.2	
other providers (1)	-01	2.11	1.15 - 3.07	2.11	27.0	5		
	-02	15.3	2.43 - 28.2	15.3	50.1	5		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 92,3%



free T4 (thyroxine) (pmol/l, N = 279)

Collective	Sample 294A- 260113	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Abbott	-01	7.34	5.87 - 8.81	7.34	6.16	31	100	96.8
	-02	21.5	17.2 - 25.8	21.5	5.77	31	96.8	
Biomerieux	-01	7.91	6.33 - 9.49	7.91	9.22	11	90.9	90.9
	-02	34.4	27.5 - 41.3	34.4	4.48	11	100	
Beckman	-01	7.38	5.90 - 8.86	7.38	18.0	19	78.9	78.9
	-02	27.1	21.7 - 32.5	27.1	8.82	19	94.7	
Siemens (Dade Behring, DPC)	-01	7.58	6.06 - 9.10	7.58	11.5	13	100	100
	-02	28.9	23.1 - 34.7	28.9	3.84	13	100	
Siemens (Bayer Health)	-01	7.71	6.17 - 9.25	7.71	9.66	15	100	100
	-02	37.3	29.8 - 44.8	37.3	5.15	15	100	
Siemens (DPC Biermann)	(1) -01	9.52	6.93 - 12.1	9.52	19.2	7		
	-02	34.6	27.7 - 41.5	34.6	11.6	7		
RadioimmunoAssay	(1) -01	9.13	7.30 - 11.0	9.13	6.58	2		
	-02	24.2	19.4 - 29.0	24.2	14.9	2		
Diasorin	(1) -01	7.64	6.11 - 9.17	7.64	4.57	6		
	-02	31.5	25.2 - 37.8	31.5	5.14	6		
Roche	-01	7.86	6.29 - 9.43	7.86	4.07	170	99.4	98.8
	-02	34.4	27.5 - 41.3	34.4	3.11	170	98.8	
other providers	(1) -01	7.98	4.68 - 11.3	7.98	24.6	5		
	-02	36.5	25.4 - 47.6	36.5	18.1	5		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 96,8%

